Breakthrough Hemolysis as a Challenging Issue in Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria (Resolution of Expert Panel)

Breakthrough Hemolysis as a Challenging Issue in Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria (Resolution of Expert Panel)  

1. Кулагин А.Д., Лисуков И.А., Птушкин В.В. и др. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии. Онкогематология. 2014;9(2):20–8. doi: 10.17650/1818-8346-2014-9-2-20-28.[Kulagin AD, Lisukov IA, Ptushkin VV, et al. National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Oncohematology. 2014;9(2):20–8. doi: 10.17650/1818-8346-2014-9-2-20-28. (In Russ)]
2. Kulagin A, Klimova O, Rudakova T, et al. Benefits and limitations of long-term eculizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH): Real-world data from large cohort study in Russia. Blood (ASH Annual Meeting Abstracts). 2018;132:2589. doi: 10.1182/blood-2018-99-120139.
3. De Fontbrune F, De Latour R. Ten years of clinical experience with eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018;55(3):124–9. doi: 10.1053/j.seminhematol.2018.04.001.
4. Lee JW, de Fontbrune FS, Lee LWL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–9. doi: 1182/blood-2018-09-876136.
5. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. 2019;133(6):540–549. doi: 10.1182/blood-2018-09-876805.
6. Hill A, Piatek CI, de Latour RP, et al. Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies. Blood. 2019;134(Suppl 1):952. doi: 10.1182/blood-2019-128929.